History
A list of downloadable documents created during development.
Background information
-
-
Appendix A: decision paper presented to the Institute's Guidance Executive
-
Appendix A: decision paper presented to the Institute's Guidance Executive (PDF 106 KB)
-
-
Appendix A: provisional matrix of stakeholders
-
-
Appendix B: proposal paper presented to the Institute's Guidance Executive
-
Appendix B: proposal paper presented to the Institute's Guidance Executive (PDF 138 KB)
-
-
A link to the summary of the responses from this consultation.
-
-
-
Review proposal: May 2009, Appendix A - Provisional matrix
-
Review proposal: May 2009, Appendix A - Provisional matrix (PDF 37 KB)
-
-
Department of Health
-
-
Royal College of Nursing
-
-
Royal College of Physicians
-
-
NHS Quality Improvement Scotland
-
-
Novartis Pharmaceuticals
-
-
Royal Pharmaceutical Society
-
-
Gilead Sciences
-
-
Royal Pharmaceutical Society
-
-
Royal College of Physicians
-
-
Royal College of Nursing
-
-
Novartis Pharmaceuticals
-
-
NHS Quality Improvement Scotland
-
-
Gilead Sciences
-
-
Department of Health
-
-
-
Hepatitis B (chronic) - adefovir dipivoxil and pegylated interferon alfa-2a: assessment report
-
-
People with chronic hepatitis B to benefit from guidance on new drugs and treatments information
-
People with chronic hepatitis B to benefit from guidance on new drugs and treatments (PDF 47 KB)
-
Appendix A
-
Appendix A - matrix of consultees and commentators
-
Appendix A - matrix of consultees and commentators (PDF 51 KB)
-
Appendix 1: Proposal comment summary table
-
Final Appraisal Determination: Hepatitis B (chronic) - adefovir dipivoxil and pegylated interferon alpha-2a
-
-
Final Appraisal Determination: Hepatitis B (chronic) - adefovir dipivoxil and pegylated interferon alpha-2a
-
-
Summary Table of Responses to the ACD: Hepatitis B (chronic) - adefovir dipivoxil and pegylated interferon alpha-2a
-
Appraisal Consultation Document: Hepatitis B (chronic) - adefovir dipivoxil and pegylated interferon alpha-2a
Evaluation report
-
Evaluation report
-
Overview
-
-
Consultee and commentator comments on the assessment report
-
British Association for Sexual Health and HIV (BASHH)
-
British Association for Sexual Health and HIV (BASHH) (PDF 18 KB)
-
Gilead Sciences
-
-
MRC Clinical Trials Unit
-
-
Roche Products Limited
-
-
Roche Products Limited (cont)
-
-
Roche Products Limited (cont)
-
-
Royal College of Nursing
-
-
Royal College of Pathologists
-
-
Royal College of Physicians
-
-
Non-manufacturer submissions
-
Royal College of Nursing
-
-
Royal College of Physicians, The British Association for the study of the Liver, and the British Society of Gastroenterology (joint submission)
-
-
Manufacturer submissions (executive summary only)
-
Gilead Sciences
-
-
Roche Products Ltd
-
-
Expert written personal statements
-
Dusheiko
-
-
Thomas
-
Final scope
-
Final scope
-
Summary of consultee and commentator comments of the draft scope
-
Summary of consultee and commentator comments of the draft scope
-
Summary of consultee and commentator comments of the draft scope (PDF 38 KB)
Summary of consultee and commentator comments on the draft matrix
-
Summary of consultee and commentator comments on the draft matrix
-
Summary of consultee and commentator comments on the draft matrix (PDF 15 KB)
Archive: Draft scope
-
Archive: Draft scope
-
Archive: Provisional matrix
-
Archive: Provisional matrix
-